Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy‐Induced Nausea and Vomiting in Children With Cancer

“…A second study evaluated the efficacy of palonosetron in preventing refractory CINV in adults who had previously received CINV prophylaxis with either granisetron or ondansetron. [25] Complete CINV control rates in the acute and delayed phases of 77% and 81% were observed, respectively. The most commonly reported adverse effects reported by patients in this study were constipation and anxiety; no patient experienced severe toxicity.…”

Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy

“…Palonosetron, which has pharmacologic and pharmacokinetic advantages over ondansetron with respect to its receptor-binding affinity and half-life [10,12] that appear to translate into significantly improved efficacy in preventing delayed CINV [13,14], is the only 5-HT 3 RA that has been granted US Food and Drug Administration approval for preventing delayed CINV. Positive clinical trial experiences in preventing both acute and delayed CINV have been described for palonosetron alone or with dexamethasone (± other agents) [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]. In contrast to other 5-HT 3 receptor antagonists, palonosetron exhibits allosteric receptor binding with positive cooperativity and triggers internalization of cell surface serotonin receptor sites [32,33].…”

Use of granisetron transdermal system in the prevention of chemotherapy-induced nausea and vomiting: a review

“…The efficacy of palonosetron in patients who have not responded to previous antiemetic treatment, in moderately or highly emetogenic chemotherapy, has been studied in a phase II clinical trial, according to different age subgroups (elderly and nonelderly patients). This clinical trial showed a high, complete antiemetic response rate with a single dose of palonosetron, irrespective of patient age 41. A recent, large phase III clinical trial which included 1114 patients receiving highly emetogenic chemotherapy, showed that palonosetron and dexamethasone are noninferior to granisetron and dexamethasone in antiemetic control of acute phase emesis, and better than granisetron and dexamethasone in the delayed phase 42…”